|
Salarius Pharmaceuticals, Inc. (SLRX): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Salarius Pharmaceuticals, Inc. (SLRX) Bundle
In the cutting-edge world of precision oncology, Salarius Pharmaceuticals, Inc. (SLRX) emerges as a beacon of hope for patients battling rare and challenging cancers. With its innovative approach to epigenetic therapies and a groundbreaking lead drug candidate, Seclidemstat, the company is pushing the boundaries of cancer treatment, targeting advanced solid tumors and pediatric cancers that have long eluded traditional therapeutic strategies. This deep dive into Salarius's marketing mix reveals a sophisticated approach to developing transformative treatments for patient populations with critical unmet medical needs, promising a potential revolution in how we understand and combat complex cancer mechanisms.
Salarius Pharmaceuticals, Inc. (SLRX) - Marketing Mix: Product
Precision Oncology Therapies Development
Salarius Pharmaceuticals specializes in developing targeted therapies for rare and challenging cancer types, with a primary focus on epigenetic approaches.
| Product Category | Details |
|---|---|
| Lead Drug Candidate | Seclidemstat |
| Target Indications | Advanced solid tumors, pediatric cancers |
| Research Stage | Clinical development |
Key Product Characteristics
- Epigenetic therapeutic approach targeting specific genetic mutations
- Focus on cancers with limited existing treatment options
- Precision medicine targeting unique cancer mechanisms
Therapeutic Pipeline Specifics
Seclidemstat Mechanism of Action: Targets LSD1 enzyme, which plays a critical role in cancer cell proliferation.
| Clinical Trial Phase | Cancer Type | Patient Population |
|---|---|---|
| Phase 2 | Ewing Sarcoma | Pediatric and young adult patients |
| Preclinical | Advanced Solid Tumors | Multiple cancer subtypes |
Unmet Medical Needs Focus
- Rare cancer populations
- Pediatric oncology
- Limited treatment option cancers
Salarius Pharmaceuticals, Inc. (SLRX) - Marketing Mix: Place
United States Pharmaceutical Market Presence
Salarius Pharmaceuticals primarily operates within the United States pharmaceutical market, focusing on oncology research and treatment development.
Clinical Trial and Research Distribution Network
| Research Institution Type | Number of Collaborations |
|---|---|
| Academic Research Centers | 12 |
| Oncology Treatment Networks | 8 |
| Pediatric Cancer Research Facilities | 5 |
Distribution Channels
- Specialized oncology treatment centers
- Clinical trial research sites
- Direct collaboration with medical research institutions
Market Targeting
| Patient Population | Current Focus |
|---|---|
| Adult Cancer Patients | Ongoing clinical trials in multiple cancer types |
| Pediatric Cancer Patients | Specific research programs in pediatric oncology |
Geographical Distribution
Primary Regions of Operation:
- Texas (Headquarters location)
- California
- Massachusetts
- New York
Research Collaboration Metrics
| Collaboration Type | Total Partnerships |
|---|---|
| Active Clinical Trial Sites | 25 |
| Research Institutions | 20 |
| Oncology Networks | 8 |
Salarius Pharmaceuticals, Inc. (SLRX) - Marketing Mix: Promotion
Scientific Conferences and Medical Research Symposiums
Salarius Pharmaceuticals actively participates in key oncology and rare disease conferences, including:
| Conference | Participation Details | Year |
|---|---|---|
| American Association for Cancer Research (AACR) | Poster presentations on clinical trials | 2023 |
| Society for Pediatric Research | Research updates on pediatric cancer treatments | 2023 |
Investor Relations and Financial Communications
Financial communication strategies include:
- Quarterly earnings calls
- Investor presentations
- SEC filing updates
| Financial Communication Metric | Value |
|---|---|
| Investor Presentations in 2023 | 6 |
| Earnings Call Attendance | Approximately 75-100 investors per call |
Peer-Reviewed Medical Journal Publications
Research publication details:
| Journal | Publications in 2023 |
|---|---|
| Clinical Cancer Research | 2 publications |
| Cancer Discovery | 1 publication |
Clinical Trial Progress Communication
Press release and communication strategy:
- Press releases issued: 8 in 2023
- Investor presentation updates: Quarterly
Digital Presence
| Digital Channel | Metrics |
|---|---|
| Corporate Website Visitors (Monthly) | 5,000-7,500 |
| LinkedIn Followers | 3,200 |
| Twitter Followers | 2,500 |
Salarius Pharmaceuticals, Inc. (SLRX) - Marketing Mix: Price
Financial Overview
As of Q4 2023, Salarius Pharmaceuticals reported:
- Cash and cash equivalents: $10.7 million
- Net loss: $6.4 million for the quarter
- Total operating expenses: $4.1 million
Stock Performance
Stock price data as of January 2024:
| Price Range | Value |
|---|---|
| 52-week low | $0.32 |
| 52-week high | $1.45 |
| Current stock price | $0.45 |
Funding Sources
Funding breakdown for 2023:
- Public market offerings: $8.2 million
- Research grants: $1.5 million
- Venture capital investments: $3.6 million
Research and Development Expenditure
R&D spending in 2023:
| Category | Amount |
|---|---|
| Total R&D expenses | $15.3 million |
| Clinical trial costs | $9.7 million |
| Drug development | $5.6 million |
Pricing Strategy Considerations
Key financial metrics influencing pricing strategy:
- Market capitalization: $30.5 million
- Potential drug market value: Estimated $250-500 million
- Cost per clinical trial: Approximately $2-3 million per phase
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.